Literature DB >> 1858953

Antagonism of endotoxic glucose dyshomeostasis by protein kinase C inhibitors.

H Inaba1, J P Filkins.   

Abstract

Activation of protein kinase C (PKC) by bacterial lipopolysaccharide had recently been implicated in the pathogenetic sequence of gram-negative sepsis, endotoxicosis, hyperinsulinism, and the alterations in glucoregulation that eventuate in glucose dyshomeostasis. This study used the peptide antibiotic polymyxin B (PMX-B) and H-7, an isoquinoline sulfonamide, as inhibitors of PKC activation to evaluate responses to provocative insulin and glucose tolerance tests in control vs. endotoxic rats. Fed male rats were treated with either Salmonella enteritidis endotoxin (ETX; 0.33 mg/kg iv) or saline 120 min before intravenous insulin tolerance testing (IVITT) with human insulin (1 U/kg) or intravenous glucose tolerance testing (IVGTT) with D-glucose (1.2 g/kg). H-7 in dimethyl sulfoxide at 25 mg/kg, PMX-B in saline at 0.25 mg/kg, or the respective vehicles were administered 5 min before the tolerance tests. Neither H-7 nor PMX-B had any significant acute effects on basal plasma glucose or lactate values. The decline in plasma with IVITT was augmented by ETX; however, concomitant H-7 or PMX-B attenuated the insulin hypoglycemia. The computed half-life of glucose in the IVGTT was decreased by ETX; however, concomitant H-7 or PMX-B decreased the tolerance alteration. In addition, both H-7 and PMX-B attenuated the rise in insulin induced by the IVGTT. Thus the hyperinsulinism and the glucoregulatory disturbances in endotoxicosis may be mediated by PKC activation and ameliorated by PKC inhibition.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1858953     DOI: 10.1152/ajpregu.1991.261.1.R26

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  4 in total

1.  Inactivation of protein kinase C in rat liver during late hypoglycemic phase of sepsis.

Authors:  C Hsu; H C Jao; S L Yang; H K Hsu; M S Liu
Journal:  Mol Cell Biochem       Date:  1998-04       Impact factor: 3.396

2.  US Food and Drug Administration Regulation of Medical Devices and Radiation Oncology: Can Reform Improve Safety?

Authors:  Jona A Hattangadi; James T O'Reilly; Abram Recht
Journal:  J Oncol Pract       Date:  2011-12-13       Impact factor: 3.840

3.  Modification of hepatic protein kinase C with phorbol myristate acetate and staurosporine alters hemodynamics in the perfused rat liver.

Authors:  H Inaba; M Araki; T Numai; T Mizuguchi
Journal:  J Anesth       Date:  1993-01       Impact factor: 2.078

4.  K252a, a potent protein kinase inhibitor, improves endotoxic lethality and glucose dyshomeostasis.

Authors:  H Inaba; T Numai; M Araki; T Mizuguchi
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.